MASS SPECTROMETRY OF URINARY NUCLEOSIDES

尿核苷的质谱分析

• 批准号: 3184960
• 负责人: KARL H SCHRAM
• 金额: $ 8.34万
• 依托单位: UNIVERSITY OF ARIZONA
• 依托单位国家: 美国
• 财政年份: 1986
• 资助国家: 美国
• 起止时间: 1986-09-30 至 1989-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3184960
• 关键词: breast neoplasm /cancer diagnosis; human therapy evaluation; human tissue; leukemia; mass spectrometry; neoplasm /cancer diagnosis; noninvasive diagnosis; nucleosides; urinalysis

Literature references attest to the potential utility of nucleoside levels in the urine of cancer patients as "biological markers" for the diagnosis and monitoring of cancer. However, current methods of analysis are prone to interferences and lack the sensitivity necessary to quantate "rare" nucleosides. GCMS methods will, therefore, be used to quantate selected nucleosides in the urine of cancer patients by the stable isotope dilution and metastable ion monitoring techniques. In addition, mass spectrometry will be used to determine the structures of unknown nucleosides in cancer patient urine which may provide a better understanding of the biochemistry of cancer cells. Urine of cancer patients will be provided by my clinical collaborators and will include samples from persons with breast cancer, cancer of the colon and leukemia. Urine samples will be obtained upon diagnosis, during treatment and following therapy. Results will then be compared to determine the utility of urinary nucleosides as "biological markers" of cancer. Samples will be prepared and analyzed using methods developed in this laboratory. The methods have been tested using urine from normal persons and are now ready to be applied to clinical studies. The research described in this proposal has the potential of providing 1) a simple, noninvasive, rapid method for the diagnosis of cancer, 2) clinicians with a noninvasive and safe method for following the patients response to therapy, and 3) an indication of relapse by the patient.

文献参考证明了核苷水平的潜在效用 癌症患者的尿液中作为诊断的“生物标记” 和癌症监测。 然而，目前的分析方法容易 容易受到干扰，并且缺乏定量“稀有”所需的灵敏度 核苷。 因此，GCMS 方法将用于定量选定的 稳定同位素稀释癌症患者尿液中的核苷 和亚稳态离子监测技术。 此外，质谱 将用于确定癌症中未知核苷的结构 患者尿液可以帮助更好地了解生物化学 癌细胞。 癌症患者的尿液将由我的临床合作者提供 将包括来自乳腺癌、结肠癌患者的样本 和白血病。 诊断后将采集尿液样本 治疗和后续治疗。 然后将结果与 确定尿核苷作为“生物标志物”的效用 癌症。 将使用本报告中开发的方法制备和分析样品 实验室。 该方法已使用正常人的尿液进行了测试 现在已准备好应用于临床研究。 本提案中描述的研究有可能提供 1) 简单、无创、快速的癌症诊断方法，2) 临床医生采用无创且安全的方法跟踪患者 对治疗的反应，以及 3) 患者复发的迹象。